Welcome to our dedicated page for Nuvectis Pharma SEC filings (Ticker: NVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvectis Pharma, Inc. (NASDAQ: NVCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Nuvectis files reports with the U.S. Securities and Exchange Commission, including Form 8-K current reports that describe material events such as quarterly financial results, corporate updates and board appointments.
In recent Form 8-K filings, Nuvectis has reported the release of press statements covering second and third quarter financial results, business highlights and progress in its oncology pipeline. These filings reference the company’s lead program NXP900, an oral small molecule inhibitor of the SRC Family of Kinases including SRC and YES1, and its clinical development from Phase 1a dose escalation through initiation of a Phase 1b program. They also discuss NXP800, an oral small molecule GCN2 activator with reported anti-cancer activity in recurrent, platinum-resistant, ARID1a-mutated ovarian cancer.
Filings confirm that Nuvectis’s common stock trades on the Nasdaq Capital Market under the symbol NVCT and that the company is classified as an emerging growth company. Additional 8-K reports document corporate governance developments, such as the appointment of a new member to the Board of Directors.
On Stock Titan, investors can use AI-powered tools to review Nuvectis’s SEC filings, with summaries that highlight key points from lengthy documents and clarify technical language. Real-time updates from EDGAR ensure that new 8-Ks, as well as other core filings like 10-K annual reports, 10-Q quarterly reports and Form 4 insider transaction disclosures when available, are quickly reflected. This structure helps users follow how clinical progress, financial performance and corporate decisions for NVCT are communicated through official regulatory channels.
Nuvectis Pharma (NVCT): Director Matthew Kaplan purchased 11,000 shares of common stock on 11/05/2025 in an open‑market transaction coded “P” at a weighted average price of $5.84. Following this trade, he beneficially owns 124,760 shares, held directly.
The filing notes the price was a weighted average across multiple same‑day trades within a $5.81–$5.88 range, and detailed breakdowns are available upon request.
Nuvectis Pharma, Inc. filed an 8‑K to furnish a press release providing a corporate update and financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under the Exchange Act.
The company’s common stock trades on the Nasdaq Capital Market under the symbol NVCT. The filing also includes the iXBRL cover page as Exhibit 104.
Nuvectis Pharma (NVCT) reported Q3 2025 results showing higher operating spending as clinical programs progressed and licensing costs increased. Cash and cash equivalents were $35.4 million as of September 30, 2025, compared with $18.5 million at year-end 2024. The company posted a Q3 net loss of $7.5 million and a nine‑month net loss of $19.1 million. A warrant term extension recorded as an $2.4 million effect increased the total net loss attributable to common shareholders in Q3.
Operating drivers: R&D expense rose to $5.8 million in Q3 (from $2.8 million) mainly due to a $2.0 million license fee for NXP900 and higher clinical costs; G&A was $2.0 million (from $1.5 million). Year‑to‑date, R&D reached $13.1 million and G&A $6.9 million. To fund operations, Nuvectis raised capital via equity: in February 2025 it sold 3,105,000 shares at $5.00 for $14.0 million net, and in Q3 it sold 1,707,309 shares under its ATM for $13.5 million gross ($13.1 million net). Management believes current cash funds planned operations for at least 12 months.
Pipeline: NXP900 advanced into Phase 1b in August 2025; a DDI study classified it as a weak CYP3A inhibitor. The company issued a final update for NXP800 in July and will not pursue further development in ovarian cancer while assessing other indications.
Nuvectis Pharma (NVCT) reported a Form 4 for director Juan Sanchez showing the acquisition of 30,000 shares of restricted common stock on 09/22/2025 at a stated price of $0. The award vests in equal annual installments over three years beginning on the first anniversary of the grant date, contingent on his continued service on the Board.
After the reported transaction, Dr. Sanchez beneficially owned 65,150 shares directly and 415 shares indirectly as custodian for his son.
Nuvectis Pharma (NVCT) reported an initial Form 3 for a director with an event date of 09/22/2025. The filing lists beneficial ownership of 35,150 shares of common stock (direct), plus 295 shares (indirect) and 120 shares (indirect) held as custodian for a son. Table II shows no derivative securities. The form was signed by Juan Sanchez on 10/31/2025.
Nuvectis Pharma (NVCT) reported insider purchases by director Charles Mosseri‑Marlio. He indirectly acquired common stock across three open‑market transactions: 46,900 shares at $6.06 on October 23, 35,034 shares at $6.15 on October 24, and 72,836 shares at $6.28 on October 27.
Following these trades, he beneficially owned 3,136,576 shares, held indirectly through Emerald Hill Ventures SARL SPF, of which he is the beneficial owner.
Nuvectis Pharma, Inc. filed a current report to disclose that its Board of Directors appointed Juan Sanchez, MD as a new director on September 22, 2025. He will serve on the Board until his term expires at the 2026 annual meeting of stockholders, when he is expected to stand for election by stockholders.
The company states that Dr. Sanchez has no arrangements or understandings with any other person related to his appointment, no family relationships with existing directors or executive officers, and no material interests in related-party transactions as described under Item 404(a) of Regulation S-K. Nuvectis announced his appointment in a press release dated September 25, 2025, which is included as an exhibit to the report.
Form 4 Overview: On 06/20/2025, Charles Mosseri-Marlio, a 10% owner of Nuvectis Pharma, Inc. (NVCT), filed a Form 4 disclosing an open-market purchase of 5,603 shares of the company’s common stock at a price of $7.99 per share. The transaction was executed indirectly through Emerald Hill Ventures SARL SPF, an entity Mosseri-Marlio beneficially owns.
Following the purchase, the insider’s aggregate ownership rose to 2,981,806 shares held indirectly and 109,321 shares held directly. The filing lists transaction code "P," signifying a standard open-market purchase. No sales, derivative security activity, or 10b5-1 plan indications were reported.
The additional shares represent less than 0.2% of Mosseri-Marlio’s total reported holdings but still reflect continued alignment with public shareholders. The filing contains no operational updates or financial metrics beyond the share purchase details.